Latest Regulatory News

Downer EDI Limited has announced a fully franked ordinary dividend of AUD 0.141 per share for the six months ending June 2025, with payments scheduled for early October.

Whitehaven Coal reported a 53% revenue increase to $5.83 billion in FY25, driven by full-year contributions from its Queensland acquisitions. Despite a cyclical price downturn, the company strengthened its balance sheet and declared a fully franked final dividend of 6 cents per share.

EQT Holdings Limited reported record funds under management and a solid financial performance for FY25, successfully completing its three-year strategic integration program. The company’s margin recovery and dividend growth signal a confident outlook amid ongoing regulatory challenges.

Equity Trustees reports record funds under management of $254 billion and a 60% jump in statutory net profit, completing a transformative three-year strategic agenda.

Netwealth Group Limited reported a standout FY2025 with net profit rising nearly 40% and funds under administration climbing 28%, underpinning a 37.5% increase in dividends. Strategic fintech acquisitions and robust governance enhancements position the company for sustained growth.

EQT Holdings Limited reported a robust FY25 with a 60% jump in net profit and record funds under management, while completing a major acquisition integration and raising dividends.

Sipa Resources has completed a key heritage survey at its Crown Gold Project near Kalgoorlie, clearing the way for initial drilling expected to begin next month. Meanwhile, assay results from its maiden drilling in South Australia are imminent.

Canterbury Resources has announced a non-underwritten Share Purchase Plan aiming to raise approximately $0.75 million at a 9.1% discount to recent trading prices, supporting exploration and working capital needs.

Ridley Corporation Limited reported a solid FY25 with revenue up 3.1% to $1.3 billion and net profit after tax rising 8.7% to $43.3 million. The company declared a fully franked final dividend of 5.00 cents per share, signaling confidence in its diversified growth strategy.

Telix Pharmaceuticals reported a robust 63% year-over-year revenue increase in H1 2025, driven by strong sales of its precision medicine products and strategic acquisitions. The company is advancing multiple late-stage clinical trials and expanding its global manufacturing footprint.

Artrya Limited has secured FDA 510(k) clearance for its Salix Coronary Plaque module, enabling near real-time detection of high-risk coronary artery plaque and opening a lucrative U.S. market opportunity with a $950 reimbursement per scan.

Telix Pharmaceuticals reported a robust 63% increase in revenue to $390.4 million for the first half of 2025, driven by strong Illuccix sales and the acquisition of RLS Radiopharmacies. Despite this growth, the company recorded a net loss of $2.3 million, reflecting increased investments and finance costs.